Daiichi Sankyo
DSKYFDrugs in Pipeline
117
Phase 3 Programs
65
Upcoming Catalysts
11
Next Catalyst
This month
Market Overview
Stock performance and key metrics
11 upcoming, 1 past
Ramucirumab Phase 3 Est. Readout
Estimated primary completion for Ramucirumab trial (NCT04704934) in Gastric Cancer, Adenocarcinoma. Topline data typically follows completion by weeks to months.
Source10 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How DSKYF's past catalysts played out
OM 40
Hypertension
Dalteparin
Venous Thromboembolism (VTE)
Datopotamab Deruxtecan
Metastatic Non Small Cell Lung Cancer
edoxaban
Prevention
DS-5565
Pain Associated With Fibromyalgia
Ifinatamab deruxtecan
Esophageal Squamous Cell Carcinoma
Chemotherapy
Acute Myeloid Leukemia
Mirogabalin
Diabetic Peripheral Neuropathic Pain
Colesevelam hydrochloride
Type 2 Diabetes
DU-176b (edoxaban)
Venous Thromboembolism
losartan potassium
Essential Hypertension
Olmesartan medoxomil
Atherosclerosis
ofloxacin otic solution 0.3%
Otitis Media
exatecan mesylate
Esophageal Cancer
Colesevelam HCl
Type 2 Diabetes
DU-176b 30mg
Non-valvular Atrial Fibrillation
Dato-DXd
Urothelial Cancer
gemcitabine hydrochloride
Pancreatic Cancer
warfarin tablets
Stroke
Pexidartinib
Tenosynovial Giant Cell Tumor
Standard of Care (SOC)
Cardiac Disease
Welchol
Type 2 Diabetes Mellitus
DU-176b
Venous Thromboembolism
CS-8958
Influenza, Human
Eplerenone
Essential Hypertension
Eribulin
Breast Cancer
Standard of Care
Venous Thromboembolism (VTE)
Metformin HCl tablets and Colesevelam tablets
Type 2 Diabetes Mellitus
Olmesartan medoxomil 40 mg - Amlodipine 10 mg
Essential Hypertension
VKA-Based Regimen
Atrial Fibrillation
Olmesartan medoxomil tablets low dose
Metabolic Syndrome
T-DM1
HER2-Positive Primary Breast Cancer
15mg DU-176b
Venous Thromboembolism
Colesevelam
Type 2 Diabetes
edoxaban tosylate(DU-176b)
Venous Thromboembolism
Salvage Chemotherapy
AML
olmesartan medoxomil + amlodipine + hydroclororthiazide
Essential Hypertension
enoxaparin sodium
Venous Thromboembolism
CHS-0214
Rheumatoid Arthritis
Tivantinib
Metastatic Colorectal Cancer
Denosumab
Osteoporosis
DU-176b 15mg
Venous Thromboembolism
DS-1062a
Non-small Cell Lung Cancer
CPT-11 and TS-1
Colorectal Cancer
Warfarin Potassium
CTEPH
prasugrel
Diabetes Mellitus
Pemetrexed
Metastatic Non Small Cell Lung Cancer
Pioglitazone
Type 2 Diabetes Mellitus
Etoposide
Non-small Cell Lung Cancer
Clopidogrel
Peripheral Arterial Disease
Pregabalin
Pain Associated With Fibromyalgia
Nab-paclitaxel
Breast Cancer
olmesartan medoxomil + hydrochlorothiazide, if necessary
Essential Hypertension
Ramucirumab
Non-Small Cell Lung Cancer
cevimeline hydrochloride
Head and Neck Cancer
T-DXd
Advanced Cancer
Quizartinib
Leukemia
DS-8201a
Neoplasm, Gastrointestinal
Trastuzumab Deruxtecan
Gastric Cancer
CS-3150
Essential Hypertension
Patritumab Deruxtecan
Nonsquamous Non-small Cell Lung Cancer
R-DXd
Solid Cancer
Edoxaban-based Regimen
Atrial Fibrillation
Transdermal Patch
Trauma
Rivoglitazone
Type 2 Diabetes
Patritumab Deruxtecan (Fixed dose)
Non-Small Cell Lung Cancer Metastatic
Carperitide
Heart Failure, Congestive
DS-5670a
Covid19
Pactimibe, CS-505
Coronary Heart Disease
CS7017
Colorectal Cancer
Enhertu
Prostate Cancer Metastatic
DU-176b tablets
Atrial Fibrillation
Warfarin potassium tablets
Atrial Fibrillation
edoxaban tosylate
Deep Vein Thrombosis
Valemetostat
Lymphoma
SUN13837 injection
Acute Spinal Cord Injury
soblidotin
Lung Cancer
Edoxaban (DU-176b)
Atrial Fibrillation
CS-7017
Advanced Non-small Cell Lung Cancer (NSCLC)
DS-8500a 25 mg
Type 2 Diabetes Mellitus
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Thrombosis
VN-0200
Respiratory Syncytial Virus Infections
DS-3939a
Advanced Solid Tumor
Pregabalin capsules
Pain
Valemetostat Tosylate
Adult T-cell Leukemia/Lymphoma
Quizartinib High Dose
Acute Myeloid Leukemia
CS-1008
Non-small Cell Lung Cancer
DS-1040b
Acute Ischemic Stroke
HER3-DXd
Advanced Solid Tumor
FOLFOX
Malignant Solid Tumour
DS-1001b
WHO Grade II Glioma
AC220
Leukemia, Myeloid, Acute
Compound AC220
Acute Myeloid Leukemia
DS-7011a
Systemic Lupus Erythematosus
piclozotan
Parkinson's Disease
Ifinatamab deruxtecan (I-DXd)
Advanced Solid Tumor
5 mg ASB17061
Atopic Dermatitis
CS-1008 (humanized anti-DR5 antibody)
Pancreatic Cancer
DJ-927
Colorectal Cancer
U3-1287
NSCLC (Advanced Non-small Cell Lung Cancer)
10mg DS-8500a tablet
Type 2 Diabetes Mellitus
DS-8201a 5.4 mg/kg Q3W
Advanced Colorectal Cancer
Trastzumab Deruxtecan
Ovarian Cancer
CS-1008 2 mg/kg
Advanced Hepatocellular Carcinoma
U3-1402
Metastatic Breast Cancer
PLX3397
Hodgkin Lymphoma
Rivoglitazone HCl
Type 2 Diabetes
SUN13834
Atopic Dermatitis
Raludotatug deruxtecan
Advanced Solid Tumor
Pharmacological intensification based on olmesartan
Ischemic Stroke
DS-5141b
Duchenne Muscular Dystrophy
CS-917
Diabetes Mellitus, Type 2
DS3790a
Hematological Malignancies
SUN11031 20 μg/kg
Cachexia
CS7017 tablets
Metastatic Non-small Cell Lung Cancer
DS-1211b
Pseudoxanthoma Elasticum
DS-5565 tablet
Diabetic Peripheral Neuropathy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OM 40 | Phase 3 | Hypertension | - | - |
Dalteparin | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Datopotamab Deruxtecan | Phase 3 | Metastatic Non Small Cell Lung Cancer | - | - |
edoxaban | Phase 3 | Prevention | - | - |
DS-5565 | Phase 3 | Pain Associated With Fibromyalgia | - | - |
Ifinatamab deruxtecan | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
Chemotherapy | Phase 3 | Acute Myeloid Leukemia | - | - |
Mirogabalin | Phase 3 | Diabetic Peripheral Neuropathic Pain | - | - |
Colesevelam hydrochloride | Phase 3 | Type 2 Diabetes | - | - |
DU-176b (edoxaban) | Phase 3 | Venous Thromboembolism | - | - |
losartan potassium | Phase 3 | Essential Hypertension | - | - |
Olmesartan medoxomil | Phase 3 | Atherosclerosis | - | - |
ofloxacin otic solution 0.3% | Phase 3 | Otitis Media | - | - |
exatecan mesylate | Phase 3 | Esophageal Cancer | - | - |
Colesevelam HCl | Phase 3 | Type 2 Diabetes | - | - |
DU-176b 30mg | Phase 3 | Non-valvular Atrial Fibrillation | - | - |
Dato-DXd | Phase 3 | Urothelial Cancer | - | - |
gemcitabine hydrochloride | Phase 3 | Pancreatic Cancer | - | - |
warfarin tablets | Phase 3 | Stroke | - | - |
Pexidartinib | Phase 3 | Tenosynovial Giant Cell Tumor | - | - |
Standard of Care (SOC) | Phase 3 | Cardiac Disease | - | - |
Welchol | Phase 3 | Type 2 Diabetes Mellitus | - | - |
DU-176b | Phase 3 | Venous Thromboembolism | - | - |
CS-8958 | Phase 3 | Influenza, Human | - | - |
Eplerenone | Phase 3 | Essential Hypertension | - | - |
Eribulin | Phase 3 | Breast Cancer | - | - |
Standard of Care | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Metformin HCl tablets and Colesevelam tablets | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Olmesartan medoxomil 40 mg - Amlodipine 10 mg | Phase 3 | Essential Hypertension | - | - |
VKA-Based Regimen | Phase 3 | Atrial Fibrillation | - | - |
Olmesartan medoxomil tablets low dose | Phase 3 | Metabolic Syndrome | - | - |
T-DM1 | Phase 3 | HER2-Positive Primary Breast Cancer | - | - |
15mg DU-176b | Phase 3 | Venous Thromboembolism | - | - |
Colesevelam | Phase 3 | Type 2 Diabetes | - | - |
edoxaban tosylate(DU-176b) | Phase 3 | Venous Thromboembolism | - | - |
Salvage Chemotherapy | Phase 3 | AML | - | - |
olmesartan medoxomil + amlodipine + hydroclororthiazide | Phase 3 | Essential Hypertension | - | - |
enoxaparin sodium | Phase 3 | Venous Thromboembolism | - | - |
CHS-0214 | Phase 3 | Rheumatoid Arthritis | - | - |
Tivantinib | Phase 3 | Metastatic Colorectal Cancer | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
DU-176b 15mg | Phase 3 | Venous Thromboembolism | - | - |
DS-1062a | Phase 3 | Non-small Cell Lung Cancer | - | - |
CPT-11 and TS-1 | Phase 3 | Colorectal Cancer | - | - |
Warfarin Potassium | Phase 3 | CTEPH | - | - |
prasugrel | Phase 3 | Diabetes Mellitus | - | - |
Pemetrexed | Phase 3 | Metastatic Non Small Cell Lung Cancer | - | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Etoposide | Phase 3 | Non-small Cell Lung Cancer | - | - |
Clopidogrel | Phase 3 | Peripheral Arterial Disease | - | - |
Pregabalin | Phase 3 | Pain Associated With Fibromyalgia | - | - |
Nab-paclitaxel | Phase 3 | Breast Cancer | - | - |
olmesartan medoxomil + hydrochlorothiazide, if necessary | Phase 3 | Essential Hypertension | - | - |
Ramucirumab | Phase 3 | Non-Small Cell Lung Cancer | - | - |
cevimeline hydrochloride | Phase 3 | Head and Neck Cancer | - | - |
T-DXd | Phase 3 | Advanced Cancer | - | - |
Quizartinib | Phase 3 | Leukemia | - | - |
DS-8201a | Phase 3 | Neoplasm, Gastrointestinal | - | - |
Trastuzumab Deruxtecan | Phase 3 | Gastric Cancer | - | - |
CS-3150 | Phase 3 | Essential Hypertension | - | - |
Patritumab Deruxtecan | Phase 3 | Nonsquamous Non-small Cell Lung Cancer | - | - |
R-DXd | Phase 3 | Solid Cancer | - | - |
Edoxaban-based Regimen | Phase 3 | Atrial Fibrillation | - | - |
Transdermal Patch | Phase 3 | Trauma | - | - |
Rivoglitazone | Phase 3 | Type 2 Diabetes | - | - |
Patritumab Deruxtecan (Fixed dose) | Phase 2 | Non-Small Cell Lung Cancer Metastatic | - | - |
Carperitide | Phase 2 | Heart Failure, Congestive | - | - |
DS-5670a | Phase 2 | Covid19 | - | - |
Pactimibe, CS-505 | Phase 2 | Coronary Heart Disease | - | - |
CS7017 | Phase 2 | Colorectal Cancer | - | - |
Enhertu | Phase 2 | Prostate Cancer Metastatic | - | - |
DU-176b tablets | Phase 2 | Atrial Fibrillation | - | - |
Warfarin potassium tablets | Phase 2 | Atrial Fibrillation | - | - |
edoxaban tosylate | Phase 2 | Deep Vein Thrombosis | - | - |
Valemetostat | Phase 2 | Lymphoma | - | - |
SUN13837 injection | Phase 2 | Acute Spinal Cord Injury | - | - |
soblidotin | Phase 2 | Lung Cancer | - | - |
Edoxaban (DU-176b) | Phase 2 | Atrial Fibrillation | - | - |
CS-7017 | Phase 2 | Advanced Non-small Cell Lung Cancer (NSCLC) | - | - |
DS-8500a 25 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor | Phase 2 | Thrombosis | - | - |
VN-0200 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
DS-3939a | Phase 2 | Advanced Solid Tumor | - | - |
Pregabalin capsules | Phase 2 | Pain | - | - |
Valemetostat Tosylate | Phase 2 | Adult T-cell Leukemia/Lymphoma | - | - |
Quizartinib High Dose | Phase 2 | Acute Myeloid Leukemia | - | - |
CS-1008 | Phase 2 | Non-small Cell Lung Cancer | - | - |
DS-1040b | Phase 2 | Acute Ischemic Stroke | - | - |
HER3-DXd | Phase 2 | Advanced Solid Tumor | - | - |
FOLFOX | Phase 2 | Malignant Solid Tumour | - | - |
DS-1001b | Phase 2 | WHO Grade II Glioma | - | - |
AC220 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Compound AC220 | Phase 2 | Acute Myeloid Leukemia | - | - |
DS-7011a | Phase 2 | Systemic Lupus Erythematosus | - | - |
piclozotan | Phase 2 | Parkinson's Disease | - | - |
Ifinatamab deruxtecan (I-DXd) | Phase 2 | Advanced Solid Tumor | - | - |
5 mg ASB17061 | Phase 2 | Atopic Dermatitis | - | - |
CS-1008 (humanized anti-DR5 antibody) | Phase 2 | Pancreatic Cancer | - | - |
DJ-927 | Phase 2 | Colorectal Cancer | - | - |
U3-1287 | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | - | - |
10mg DS-8500a tablet | Phase 2 | Type 2 Diabetes Mellitus | - | - |
DS-8201a 5.4 mg/kg Q3W | Phase 2 | Advanced Colorectal Cancer | - | - |
Trastzumab Deruxtecan | Phase 2 | Ovarian Cancer | - | - |
CS-1008 2 mg/kg | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
U3-1402 | Phase 2 | Metastatic Breast Cancer | - | - |
PLX3397 | Phase 2 | Hodgkin Lymphoma | - | - |
Rivoglitazone HCl | Phase 2 | Type 2 Diabetes | - | - |
SUN13834 | Phase 2 | Atopic Dermatitis | - | - |
Raludotatug deruxtecan | Phase 2 | Advanced Solid Tumor | - | - |
Pharmacological intensification based on olmesartan | Phase 2 | Ischemic Stroke | - | - |
DS-5141b | Phase 2 | Duchenne Muscular Dystrophy | - | - |
CS-917 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
DS3790a | Phase 2 | Hematological Malignancies | - | - |
SUN11031 20 μg/kg | Phase 2 | Cachexia | - | - |
CS7017 tablets | Phase 2 | Metastatic Non-small Cell Lung Cancer | - | - |
DS-1211b | Phase 2 | Pseudoxanthoma Elasticum | - | - |
DS-5565 tablet | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Daiichi Sankyo's drug pipeline?→
CatalystAlert tracks 117 drug candidates in Daiichi Sankyo's (DSKYF) pipeline across Phase 3, Phase 2. Its lead program is OM 40 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Daiichi Sankyo's next FDA catalyst?→
Daiichi Sankyo's (DSKYF) next tracked catalyst is a Phase 3 expected August 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DSKYF biotech catalysts?→
Add DSKYF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Daiichi Sankyo's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.